2024
DOI: 10.1101/2024.06.05.597513
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Preclinical study of the human recombinant Erythropoietin (GBPD002) compared with Eprex®

Kakon Nag,
Mohammad Mohiuddin,
Maksudur Rahman Khan
et al.

Abstract: Erythropoietin (EPO) is a glycoprotein that an essential growth factor for erythroid progenitors at the bone marrow, which appears in blood as a response to hypoxia. It is produced mainly by the kidneys; and its biosynthesis and release are stimulated by the reduction of tissue oxygenation and/or the reduction of the mass of erythrocytes. Here, we report the results of the preclinical evaluation of the safety of ‘GBPD002’ a recombinant human erythropoietin (rhEPO) developed by the Globe Biotech Limited, Bangla… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 39 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?